Molecular testing has become an essential tool in the evaluation of borderline lymphoid and melanocytic lesions. Integration of morphological, immunophenotypic and molecular information guides the dermatopathologist in differentiating between benign and malignant lesions.
- Clonality testing (gene rearrangement studies) for cutaneous T- and B-cell lymphomas
- Detection of mutational status for melanoma (BRAF V600E mutation)
In addition, in collaboration with Genomic Pathology Services (GPS) at Washington University, we offer next-generation sequencing to detect mutations in a comprehensive set of cancer-related genes.
Please contact us for information regarding specific tests.